Ticlopidine enhances the platelet inhibitory capacity of abciximab in vitro

Journal of Thrombosis and Thrombolysis

Volumn 9, Issue 1, 2000, Pages 29-36

  Kleiman, Neal S ^a,c   Graziadei, Nikki ^a   Jordan, Robert E ^b   Lance, Ellen T ^b   Fischer, Anthony ^a   Maresh, Kelly ^a   Edwards, Amy ^a   Mascelli, Mary Ann ^b  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b CENTOCOR INC   (United States)

^c MS F 1090 ^*  (United States)

Author keywords

Abciximab; Platelet inhibition; Ticlopidine

Indexed keywords

ABCIXIMAB; ADENOSINE DIPHOSPHATE; THROMBIN RECEPTOR ACTIVATING PEPTIDE; TICLOPIDINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG MONITORING; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; STENT; THROMBOCYTE AGGREGATION INHIBITION; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 0033979125     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1018631810977     Document Type: Article

References (31)

1. Schomig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996;334:1084-1089.
2. Hall P, Nakamura S, Maiello L, et al. A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation. Circulation 1996;93:215-222.
3. Colombo A, Hall P, Nakamura S, et al., Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation 1995;91:1676-1688.
4. Di Minno G, Cerbone AM, Mattioli PL, Turco S, Iovine C, Mancini M. Functionally thrombasthenic state in normal platelets following the administration of titiclopidine. J Clin Invest 1985;75:328-338.
5. Kuzniar J, Splawinska B, Malinga K, Mazurek AP, Splawinski J. Pharmacodynamics of ticlopidine: Relation between dose and time of administration to platelet inhibition. Int. J Clin Pharm Ther 1996;34:357-361.
6. Buur T, Larsson R, Berglund U, Donat F, Tronquet C. Pharmacokinetics and effect of ticlopidine on platelet aggregation in subjects with normal and impaired renal function. J Clin Pharm 1997;37:108-15.
7. Heptinstall S, May JA, Glenn JR, Sanderson HM, Dickinson JP, Wilcox RG. Effects of ticlopidine administered to healthy volunteers on platelet function in whole blood. Thromb Haem 1995;74:1310-35.
8. Droste DW, Siemens HJ, Sonne M, Kaps M, Wagner T. Hemostaseologic and hematologic parameters with aspirin and ticlopidine treatment in patients with cerebrovascular disease - A cross-over study. J Card Pharm 1996;28:591-594.
9. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-961.
10. Topol EJ, Califf RM, Weisman HF, et al. Randomized trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: Results at six months. Lancet 1994;343:1434-1435.
11. The EPILOG Investigators. Platelet glycoprotein II/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Eng J Med 1997;336:1689-1696.
12. The Capture Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina -the Capture study. Lancet 1997;349:1429-1435.
13. Tcheng JE, Ellis SG, George BS, et al. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation 1994;90:1757-1764.
14. Kleiman NS, Raizner AE, Jordan R, et al. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: Implications for inhibition of the internal pool of GPIIb/IIIa receptors. J Am Coll Cardiol 1995;26:1665-1671.
15. Konstantopoulos K, Kamat SG, Schafer AI, et al. Shear-induced platelet aggregation is inhibited by in vivo infusion of an anti-glycoprotein IIb/IIIa antibody fragment, c7E3 Fab, in patients undergoing coronary angioplasty. Circulation 1995;91:1427-1431.
16. Vu T-KH, Wheaton VI, Hung DT, Charo I, Coughlin SR. Domains specifying thrombin receptor interaction. Nature 1991;353:674-677.
17. Born GVR. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962;194:927-929.
18. Defreyn G, Bernat A, Delebassee D, Maffrand JP. Pharmacology of ticlopidine: A review. Semir Thromb Hemo 1989;15:159-166.
19. Mascelli, MA, Worley S, Veriabo NJ, et al. Rapid assessment of platelet function using a modified whole blood aggregometer in PTCA patients receiving anti-GPIIb/IIIa therapy. Circulation 1997;96:3860-3866.
20. Mascelli, MA, Lance ET, Damaraju L, Wagner CL, Weisman HF, Jordan RE. The pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GPIIb/IIIa receptor blockade. Circulation 1998;97:1680-1688.
21. Gawaz M, Neumann FJ, Ott I, May A, Schomig A. Platelet activation and coronary stent implantation - Effect of antithrombotic therapy. Circulation 1996;94:279-285.
22. Tohgi H, Takahashi H, Kashiwaya M, Watanabe K. Effect of plasma fibrinogen concentration on the inhibition of platelet aggregation after ticlopidine compared with aspirin. Stroke 1994;25:2017-2021.
23. Gachet C, Cattaneo M, Ohlmann P, et al. Purinoceptors on blood platelets: Further pharmacological and clinical evidence to suggest the presence of two ADP receptors. Br J Haematol 1995;91:434-444.
24. Neumann FJ, Ott I, Gawaz M, Puchner G, Schomig A. Neutrophil and platelet activation at balloon-injured coronary artery plaque in patients undergoing angioplasty. J Am Coll Cardiol 1996;27:819-824.
25. Scharf RE, Tomer A, Marzec UM, Teirstein PS, Ruggeri ZM, Harker LA. Activation of platelets in blood perfusing angioplasty-damaged coronary arteries: Flow cytometric detection. Arterioscler Thromb 1992;12:1475-1487.
26. Humbert M, Nurden P, Bihour C, et al. Ultrastructural studies of platelet aggregates from human subjects receiving clopidogrel and from a patient with an inherited defect of an ADP-dependent pathway of platelet activation. Arterioscler Thromb Vase Biol 1996;16:1532-1543.
27. Cattaneo M, Lombardi R, Bettega D, Lecchi A, Mannucci PM. Shear-induced platelet aggregation is potentiated by desmopressin and inhibited by ticlopidine. Arteriocler Thromb 1993;13:393-397.
28. de Maat MP, Arnold AE, van Buuren S, Wilson JH, Kluft C. Modulation of plasma fibrinogen levels by ticlopidine in healthy volunteers and patients with stable angina pectoris. Thromb Haemost 1996;76:166-170.
29. Gryglewski RJ, Korbut R, Swies J, Kostka Trabka E, Bieron K, Robak J. Thrombolytic action of ticlopidine: Possible mechanisms. Eur J Pharm 1996;308:61-67.
30. Nurden P, Bihour C, Smith M, Raymond JM, Nurden AT. Platelet activation and thrombosis -Studies in a patient with essential thrombocythemia. Am J Hematol 1996;51:79-84.
31. Gregorini L, Marco J, Fajadet J, et al. Ticlopidine and aspirin pretreatment reduces coagulation and platelet activation during coronary dilation procedures. J Am Coll Cardiol 1997;29:13-20.